Table S3.
Subgroup analysis for FINS of various variables
| Group | Number of studies | WMD (95% CI) | P for heterogeneity | I2 % |
| Total | 7 | -1.43 [-2.78, -0.09] | < 0.001 | 97.00 |
| PG | ||||
| NGR | 4 | -0.65 [-3.86, 2.56] | < 0.001 | 98.00 |
| IGT or DM | 3 | -2.79 [-10.92, 5.34] | < 0.001 | 96.00 |
| Dosage | ||||
| Allopurinol ≥ 300 mg/d | 3 | -3.52 [-10.68, 3.64] | < 0.001 | 94.00 |
| Allopurinol < 300 mg/d | 2 | 3.31 [-4.40, 11.01] | < 0.001 | 99.00 |
| benzbromarone 50 mg/d | 1 | -7.80 [-10.31, -5.29] | - | - |
| Adjust according to SUA | 1 | -0.51 [-0.73, -0.29] | - | - |
| Mean SUA at baseline | ||||
| ≥ 420 umol/L | 4 | 0.35 [-13.48, 14.17] | < 0.001 | 90.00 |
| < 420 umol/L | 3 | -1.27 [-2.02, -0.52] | < 0.001 | 98.00 |
| Reduction of SUA | ||||
| ≥ 150 umol/L | 3 | -2.82 [-10.90, 5.26] | < 0.001 | 96.00 |
| < 150 umol/L | 4 | -0.49 [-3.53, 2.55] | < 0.001 | 97.00 |
| Mean age | ||||
| ≥50 years | 5 | -1.47 [-2.31, -0.63] | < 0.001 | 91.00 |
| <50 years | 2 | -1.60 [-19.08, 15.88] | < 0.001 | 99.00 |
| BMI | ||||
| ≥ 28 | 3 | -1.09 [-2.49, 0.30] | 0.005 | 81.00 |
| < 28 | 3 | -0.20 [-6.43, 6.03] | < 0.001 | 98.00 |
| Duration | ||||
| ≥6 months | 3 | -2.79 [-10.92, 5.34] | < 0.001 | 96.00 |
| <6 months | 4. | -0.65 [-3.86, 2.56] | < 0.001 | 98.00 |
| Number of participant | ||||
| >60 | 4 | -0.77 [-1.23, -0.32] | < 0.001 | 73.00 |
| ≤60 | 3 | -3.65 [-15.67, 8.36] | < 0.001 | 99.00 |
Abbreviations: PG, plasma glucose; NGR, normal glucose regulation; IGT, impaired glucose tolerance; DM, diabetes mellitus; SUA, serum uric acid; BMI, body mass index.